SPHYGMOMANOMETER MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• On February 27, 2024, Aktiia, a Switzerland-based health tech innovator, announced the completion of a USD 30 MN (CHF 27 MN) investment round headed by Redalpine. This strategic capital infusion will help Aktiia accelerate its objective to reduce the global burden of hypertension by offering revolutionary insights into blood pressure management via AI-driven technology, which is already used by over 60,000 customers and dozens of healthcare organizations.
• On January 04, 2024, Nanowear, a leader in healthcare-at-home remote diagnostics, announced that SimpleSense, its nanotechnology-enabled wearable and software platform, had been granted U.S. FDA 510(k) approval for a revolutionary AI-enabled Software-as-a-Medical Device (SaMD). SimpleSense-BP, the first non-invasive, cuffless, continuous blood pressure monitor and diagnostic, is a transformative tool in clinical diagnostic management of hypertension and complements the wearable platforms previously cleared cardiopulmonary diagnostics.
• In January 2023, iProven, a leading manufacturer of healthcare devices, announced the launch of the BPM-417 Blood Pressure Monitor, a revolutionary device with a number of innovative features that allow users to effortlessly monitor and track their blood pressure. One of the BPM-417's notable features is its wrist guide position, which assists users in properly positioning their wrist for precise readings.
• In May 2021, Biobeat, a global leader in wearable remote patient monitoring solutions for the healthcare continuum, announced the launch of its new wearable and continuous ambulatory blood pressure monitoring (ABPM) chest monitor. Biobeat's disposable wearable chest monitor is an easy and intuitive patient self-setup that requires no assistance from a clinician or professional.